复星医药拟分拆复星安特金于香港联交所上市

Core Viewpoint - Fosun Pharma plans to spin off its subsidiary Fosun Antigen, which operates in the vaccine sector, for a listing on the Hong Kong Stock Exchange to enhance corporate governance and sustainable development, ultimately maximizing shareholder value [1] Group 1 - The proposed spin-off aims to improve the governance level and sustainable development of Fosun Antigen, which is a platform for the group's vaccine business [1] - The spin-off is expected to broaden financing channels and enhance market competitiveness for Fosun Antigen [1] - This move will further deepen the group's layout in the vaccine field, strengthening the overall competitiveness of the group [1]